These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 36748748

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
    Huntley D, Giménez E, Pascual MJ, Hernández-Boluda JC, Gago B, Vázquez L, Piñana JL, García M, Pérez A, Serrano D, Hernández M, Albert E, Solano C, Navarro D.
    Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
    [Abstract] [Full Text] [Related]

  • 23. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment.
    Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Piñana JL, Navarro D, Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH).
    Bone Marrow Transplant; 2021 Jun; 56(6):1281-1290. PubMed ID: 33319853
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
    Chen K, Arbona-Haddad E, Cheng MP, McDonnell AM, Gooptu M, Orejas JL, Timblin K, Silverman E, Al-Hamed R, Soiffer RJ, Hammond SP, Marty FM.
    Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
    Saullo JL, Baker AW, Snyder LD, Reynolds JM, Zaffiri L, Eichenberger EM, Ferrari A, Steinbrink JM, Maziarz EK, Bacchus M, Berry H, Kakoullis SA, Wolfe CR.
    J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H, Mutlu E, Köksoy S, Yılmaz VT, Koçak H, Çolak D, Mutlu D, Günseren F, Dinçkan A, Aliosmanoğlu İ, Süleymanlar G, Gültekin M.
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [Abstract] [Full Text] [Related]

  • 35. Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
    Solano C, Giménez E, Piñana JL, Albert E, Vinuesa V, Hernández-Boluda JC, Amat P, Navarro D.
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28471073
    [Abstract] [Full Text] [Related]

  • 36. Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
    Huntley D, Giménez E, Pascual MJ, Remigia MJ, Amat P, Vázquez L, Hernández M, Hernández-Boluda JC, Gago B, Piñana JL, García M, Martínez A, Mateo E, Gozalbo-Rovira R, Albert E, Solano C, Navarro D.
    Bone Marrow Transplant; 2020 Jul; 55(7):1347-1356. PubMed ID: 32205853
    [Abstract] [Full Text] [Related]

  • 37. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients.
    Kachur E, Roshdy D, Hamadeh I, Dodd B, Shahid Z.
    Transpl Infect Dis; 2021 Apr; 23(2):e13502. PubMed ID: 33171005
    [Abstract] [Full Text] [Related]

  • 38. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
    Fukuda M, Hattori J, Ohkubo R, Watanabe A, Maekawa S.
    Clin Drug Investig; 2024 Jul; 44(7):527-540. PubMed ID: 38935253
    [Abstract] [Full Text] [Related]

  • 39. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, Desai S, King C.
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.